Lyell Immunopharma
The Director, Clinical Science at Lyell will partner with medical monitors and cross‑functional teams to design, execute, and oversee clinical trials for next‑generation CAR T‑cell therapies, ensuring compliance with regulatory standards and GCP. The role focuses on study medical monitoring for pivotal programs and supports protocol design, data interpretation, and regulatory submissions.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2018
Lyell is a fully integrated biopharmaceutical company developing next‑generation T‑cell reprogramming technologies to create durable CAR T‑cell therapies for hematologic malignancies and solid tumors. Their platform-driven approach spans discovery through clinical development, with active programs and trials such as the PiNACLE study for aggressive B‑cell non‑Hodgkin lymphoma and the recently acquired GCC‑targeted candidate LYL273. Lyell is patient‑focused, aiming to improve outcomes for cancers with significant unmet medical need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Lyell Immunopharma.
3% above the average for this role
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation
5 days ago
Executive Medical Director, Oncology Clinical Development
AbbVie
Scientific Director, Oncology Early Development
AbbVie
Senior Medical Director, Oncology Early Development
AbbVie
Global Development Scientist, Senior Manager
AstraZeneca
Associate Medical Director
ICON plc
Scientific Director, Oncology Early Development
AbbVie